Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01267812 · ClinicalTrials.gov registry record · Phase 2
Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation
A Phase 2 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT01267812 is a Phase 2 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 23 participants.
The verdict
NCT01267812, a Phase 2 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving bortezomib together with rituximab may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving bortezomib and rituximab together works in treating patients with mantle cell lymphoma who have previously undergone stem cell transplantation
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL rituximab
- OTHER immunohistochemistry staining method
- GENETIC RNA analysis
- DRUG bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2011-10-03 |
| Est. Completion | 2020-11-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01267812
The ClinicalTrials.gov registry entry for NCT01267812 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01267812 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01267812 about?
NCT01267812 is a clinical study titled "Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation". RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill the...
What is the current status of trial NCT01267812?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2011-10-03. Estimated completion is 2020-11-02.
What interventions are being tested in trial NCT01267812?
The interventions under investigation include: laboratory biomarker analysis (OTHER), rituximab (BIOLOGICAL), immunohistochemistry staining method (OTHER), RNA analysis (GENETIC), bortezomib (DRUG).
Who is sponsoring clinical trial NCT01267812?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.